AbbVie raised its full-year adjusted earnings forecast after third-quarter revenue increased 10.3% to $17.404 billion. The results, released on 30 October, cover the quarter ended 30 September 2026.
Reported diluted earnings per share were $2.37, compared with $3.82 on the company’s adjusted measure. Both figures include an unfavorable $0.11 per-share effect from acquired in-process research and development and milestone expenses.
Results and accounting basis
Q3 2026 | ended 30 September 2026. Amounts are US dollars unless stated otherwise. Primary source observed 2026-10-31T08:57:41.578Z.
| Measure or timetable | Verified figure and basis | Primary evidence |
|---|---|---|
| Q3 net revenue | $17.404bn; +10.3% reported | AbbVie official results |
| Q3 operational revenue growth | 10.5%; company-adjusted currency basis | AbbVie official results |
| Q3 diluted EPS: GAAP / adjusted | $2.37 / $3.82 | AbbVie official results |
| Expense retained in both Q3 EPS measures | Unfavorable $0.11 per share: acquired IPR&D and milestones | AbbVie official results |
| 2026 adjusted-EPS forecast | $13.95–$13.99; previously $13.76–$13.96 | AbbVie official results |
| YTD acquired IPR&D/milestone impact in forecast | Unfavorable $0.69 per share through Q3 | AbbVie official results |
Growth rates and earnings labels need separate checks
The 10.3% reported revenue increase and 10.5% operational increase are different presentations of sales growth. Operational growth should not be described as the reported percentage or as a direct measure of units sold.
AbbVie reported immunology revenue of $9.165 billion, up 16.3% on a reported basis. The neuroscience portfolio contributed $3.389 billion, up 19.4% reported. These are parts of group revenue, not additional amounts to add to the $17.404 billion total.
What the higher annual forecast includes
The new 2026 adjusted diluted-EPS range is $13.95 to $13.99, replacing $13.76 to $13.96. It includes the unfavorable $0.69 per-share acquired-research and milestone expense impact incurred over the first nine months. The quarter’s $0.11 effect and the nine-month $0.69 effect cover different periods.
Acquired in-process research and development refers to research obtained through transactions before a finished product is available. The expense label is distinct from recognized sales. AbbVie’s adjusted EPS remains a supplementary non-GAAP measure; the annual range is management’s forecast, not an achieved result.
What to watch
Watch delivery against the adjusted annual forecast and the issuer’s reconciliations. Neither the forecast nor drug-program progress guarantees future revenue or investor returns.
Primary source record
AbbVie Inc. — exact document: https://news.abbvie.com/2026-10-30-AbbVie-Reports-Third-Quarter-2026-Financial-Results. Observed 2026-10-31T08:57:41.578Z. The issuer’s release is primary evidence for its own results, not independent corroboration.
Additional primary record
AbbVie Inc. — https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20261030.htm; checked 2026-10-31T09:06:13.082Z. Same issuer earnings announcement formally furnished through its 8-K; not an independent second report. Relevant event/period/filing context only where stated.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.